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tions such as emergency and elective surgery, se-
vere medical diseases, traumas, childbirth, burns,
natural disasters, war and torture. Relieving pain is
hampered by political conflicts, social disruption
and limited analgesic supplies in many places and,
although a number of developed countries have in-
troduced acute pain teams, pain relief is still in-
sufficient in a number of medical settings (6). The
1995 SUPPORT study found that one-half of the
patients with life-limiting diseases experienced
moderate to severe pain during their last days (7),
and subsequent studies have shown that 40% of
postoperative patients report moderate or severe
pain, and inadequate pain relief (8, 9). 
Chronic pain has been defined by the American
Society of Interventional Pain Physicians (ASIPP)
as “pain that persists six months after an injury and
beyond the usual course of an acute disease or a
reasonable time for a comparable injury to heal,
that is associ ated with chronic pathologic process-
es that cause continuous or intermittent pain for
months or years that may continue in the presence
or absence of demonstrable pathology; may not be
amenable to routine pain control methods; and
healing may never occur” (10). The many clinical
INTRODUCTION
Patients fear pain because it causes considerablesuffering, and clinicians may not handle it ap-
propriately because they fail to understand it (1).
The International Association for the Study of Pain
(IASP) defines it as “… is an unpleasant sensory
and emotional experience associated with actual
or potential tissue damage, or described in terms of
such damage” (2). Individual patients perceive it
differently, depending on the context of the stimu-
lus, their previous experience, and their current
psychological and physical condition. Furthermore,
painful stimuli cannot be ignored, disturb behav-
ioural and cognitive activities, and give rise to anx-
iety and/or depression (3, 4). 
Acute pain is one of the most frequent reasons for
consulting a doctor in all parts of the world (5), and
is often associated with already distressing situa-
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RIASSUNTO
Questo studio analizza le principali evidenze scientifiche relative a ketoprofene, farmaco anti-infiammatorio non ste-
roideo, nel trattamento del dolore acuto, cronico e post-operatorio. Nei pazienti con dolore di origine reumatica e
post-traumatica, ketoprofene si è dimostrato efficace e ben tollerato, anche negli anziani. Nel trattamento del dolore
post-operatorio, ketoprofene presenta in alcuni studi un’efficacia simile agli oppioidi, con possibile beneficio anche
nella prevenzione delle calcificazioni eterotopiche conseguenti a interventi di chirurgia ortopedica maggiore, senza
interazioni con i processi riparativi dell’osso. In conclusione, ketoprofene rappresenta una valida opzione terapeuti-
ca nel trattamento del dolore di natura reumatica e traumatica e del dolore post-operatorio.
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conditions characterised by chronic pain are gen-
erally described on the basis of the site (e.g. back,
head, viscera) and type of injury (e.g. neuropathic,
arthritic, cancer, myofascial, diabetic). In particu-
lar, neuropathic pain develops as a result of lesions
or disease affecting the somatosensory nervous sys-
tem either in the periphery or centrally. Neuro-
pathic pain is characterized by spontaneous ongo-
ing or shooting pain and evoked amplified pain re-
sponses after noxious or non-noxious stimuli (11).
Another group of syndromes are classified as cen-
tral sensitivity syndromes or functional somatic
syndromes or medically unexplained clinical con-
ditions (fibromyalgia, irritable bowel syndrome,
chronic fatigue syndrome, migraine headache,
chronic back pain); they frequently overlap and
give rise to different pain localizations (12). This
suggests that modulating pain-related information
may be related to the onset and/or maintenance of
chronic pain: the best example is possibly fi-
bromyalgia because it is very difficult to determine
the type of injured tissue, and the degree of mus-
culoskeletal pain, fatigue and sleep alterations dif-
fers widely among patients and may be masked by
sometimes numerous other symptoms (13).
A number of physiological mechanisms may cause
injuries to give rise to nociceptive responses and ul-
timately pain (14). In response to painful stimuli,
action potentials are transmitted by sensory fibres
to the cell bodies of the corresponding primary sen-
sory neurons in the dorsal root ganglia (DRG). The
most important peripheral nerve fibres are the A
and C primary sensory afferent fibres, which car-
ry pain signals from peripheral mechanical, thermal
and chemical stimuli, and reach spinal neurons as
a result of synaptic transmission within the dorsal
horn of the spinal cord. Many neurotransmitters
(glutamate, substance P, etc.) modulate post-synap-
tic responses and induce further transmission to
supraspinal sites (the thalamus, the anterior cingu-
lated cortex, the insular cortex, and the so-
matosensory cortex) via the ascending pathways
(15). The extended or intense dorsal horn neuron
activity caused by repeated or sustained stimulation
may then increase neuronal responsiveness (14).
In the case of peripheral sensitisation, heightened
neuron excitability occurs where the pain impulse
originates whereas, in the case of central sensiti-
sation, it occurs in the spinal neurons. The repeat-
ed stimulation of certain spinal neurons causes
them to fire more frequently, thus intensifying the
pain and making it last much longer than the stim-
ulus itself. Increased nociception to normally in-
nocuous stimuli such as a light touch (allodynia) or
an excessive painful response to a painful stimulus
such as a pinprick (hyperalgesia) involve plastici-
ty by altering multiple neurotransmitters and in-
tracellular signalling events in the spinal cord dor-
sal horn (SCDH) neurons (16).
The pain due to sensitisation does not only come
from the site of injury, but also from neural mes-
sages or impulses. Nerve damage can lead to neu-
ropathic pain, which lasts much longer than the in-
jury itself, greatly exceeds a “normal” response to
a painful stimulus, and may also spread to other
parts of the body. This process plays a major role
in the development of chronic pain. 
The spinal cord mechanism of pain amplification
is transmitted to the nociceptive neurons in the dor-
sal horn through unmyelinated C fibres. The N-
methyl-D-aspartate (NMDA) receptors of second-
order neurons are activated during the course of
the C-fibre transmission of stimuli. This induces
calcium entry into dorsal horn neurons (14), which
activates nitric oxide (NO) synthase and leads to
NO synthesis. NO can affect nociceptor terminals
and enhance the release of sensory neuropeptides
(particularly substance P) from presynaptic neu-
rons, which contributes to the development of hy-
peralgesia and the maintenance of central sensiti-
sation (14). 
The presence of several pain inhibitory and facili-
tatory centers in the brainstem is well recognized.
The dorsolateral funiculus appears to be a preferred
pathway for descending pain inhibitory systems.
Disruption of one or more of the elements of the
inhibitory system can result in the equivalent of
central sensitization (14).
A variety of different mediators may play a role in
the pain system. For example, increasing evidence
has provided better understanding of the roles of
both immune and pro-inflammatory mediators such
as the eicosanoids, bradykinins, serotonin,
ATP/ADP, neurotrophins, cytokines, chemokines,
and reactive oxygen species (17). These mediators
are not exclusive to cells of immune/inflammato-
ry origin, but they are also produced by Schwann
cells and spinal glial cells, thereby potentially me-
diating the mechanism of neuropathic pain. Mito-
gen-activated protein kinases (MAPKs) family are
important for intracellular signal transduction and
play critical roles in regulating neural plasticity and
inflammatory responses. Accumulating evidence
shows that all MAPK pathways contribute to pain
sensitization after tissue and nerve injury via dis-
tinct molecular and cellular mechanisms (18). The
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discovery that glial activation plays a critical role
in modulating neuronal functions and affects the
spinal processing of nociceptive signalling has led
to new insights into the mechanisms underlying
the central sensitisation involved in chronic pain fa-
cilitation. Spinal glial activation is a major con-
tributor to the development and maintenance of al-
lodynia and hyperalgesia in various models of
chronic pain, including neuropathic pain and the
pain associated with peripheral inflammation, and
is also involved in some forms of visceral hyperal-
gesia. Development of specific inhibitors which
will modulate mediators targeting neurons and glial
cells may lead to new therapies for pain manage-
ment (18). 
Some cognitive styles and personality traits, such
as somatisation, catastrophising and hypervigi-
lance, have been associated with the amplification
and extent of pain even in the absence of tissue
damage (19). Behavioural and cognitive therapies
may therefore also effect synaptic transmission in
the spinal cord via the descending pathways, and
thus prevent or reverse long-term changes in synap-
tic strength in the pain pathways.
Pain is a leading cause of morbidity worldwide,
with published data showing its prevalence as high
as 50% for chronic pain in the European popula-
tion. This prevalence is likely to continue to rise,
particularly in elderly people with comorbid con-
ditions and pain of complex etiologies. There is
thus a rapidly growing demand for safe and effec-
tive pain management. Adequate and appropriate
pain assessment in the clinic is an important pre-
requisite in formulating a pain management plan,
although there is considerable evidence that this is
often not done outside the specialist setting.
Management of mild-to-moderate pain has tradi-
tionally been based upon the use of non-steroidal
anti-inflammatory drugs (NSAIDs) and the syn-
thetic non-opioid analgesic paracetamol (aceta-
minophen). Both NSAIDs and paracetamol are ef-
fective, widely recommended and extensively used.
On the other hand, selective cyclooxygenase-2
(COX-2) inhibitors were developed to reduce gas-
trointestinal side effects and complications, but
large-scale studies have highlighted an even more
serious potential effect: cardiovascular events. Both
the European Medicines Agency (EMA) and the
Food and Drugs Administration (FDA) in the US
have issued advice to apply cautions and restric-
tions when prescribing COX-2 inhibitors, particu-
larly for patients at increased cardiovascular risk
and for long-term use. If pain persists or increas-
es, weak opioids, such as codeine, dextro-
propoxyphene or tramadol, or even strong opioids,
such as morphine or fentanyl, can be used in com-
bination with NSAIDs or paracetamol, in order to
control pain. 
NSAIDs play a major role in the management of
pain in acute and chronic rheumatic diseases, as
well as post-surgical pain, considering the fact that
these drugs, unlike paracetamol, are also able to re-
lieve inflammation associated to these types of
pain. The well known gastrointestinal-related side
effects from NSAIDs can be reduced by careful at-
tention to dose and duration of therapy, and may be
prevented and treated by using appropriate thera-
py in combination with NSAIDs. 
KETOPROFEN LYSINE SALT
Ketoprofen is a NSAID belonging to the family of
propionic derivates, with analgesic, anti-inflam-
matory and antipyretic properties (20). It repre-
sents a racemic mixture, from which only the S-iso-
mer possesses cyclo-oxygenase inhibiting activity,
while the R-isomer is far less potent (21, 22). Sal-
ification of ketoprofen with the lysine amino acid
allowed an improvement of the molecules charac-
teristics (23, 24). In particular, ketoprofen lysine
salt (KLS) has a higher solubility when compared
to acid ketoprofen; this characteristic facilitates a
more rapid and complete absorption of the active
principle, with a high serum peak concentration
reached after 15 minutes following oral adminis-
tration of KLS compared to 60 minutes after keto-
profen administration (Fig. 1) (25-27). This rapid
increase in peak plasma concentration of the KLS
consequently results in a more rapid pharmaco-
logical activity, with an analgesic activity observed
only 30 minutes after the first oral administration
in a statistically significant modality compared to
placebo (28). Moreover, the excellent solubility of
KLS in aqueous solution allows the possibility to
use injectable preparations with a similar physio-
logical pH without the need for preservative, pos-
sibly reducing irritant reactions and tissue damage
at the application site. 
The main mechanism of analgesic action of KLS
is the inhibition of cyclo-oxygenase and, conse-
quently, decreased production of prostaglandin E2
(PGE2). In addition to its effects on cyclo-oxyge-
nase, ketoprofen also inhibits the lipoxygenase
pathway of the arachidonic acid cascade (29) lead-
ing to a decrease in the synthesis of leukotrienes. 
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Interestingly, it has been shown that ketoprofen, as
other NSAIDs, has both peripheral and central sites
of action (30) through the inhibition of central
prostaglandin biosynthesis (31, 32), inhibiting both
brain cyclo-oxygenase (COX) and nitric oxide syn-
thase. Actually, ketoprofen is rapidly and readily
distributed into the central nervous system passing
the blood brain barrier within 15 minutes, thanks
to its high level of liposolubility (33). It has been
recently demonstrated that, besides the inhibition
of prostaglandin synthesis at the central level, ke-
toprofen interacts with the 5-HT system, thus lead-
ing to the hypothesis that this characteristic may ex-
plain the higher efficacy observed versus other
NSAIDs (22, 30, 34). 
These properties make ketoprofen a suitable choice
for the management of symptoms associated with
musculoskeletal inflammation in both acute and
chronic settings (35). It is a highly potent and high-
ly effective NSAID in relieving pain from trau-
matic, orthopaedic and rheumatic disorders be-
cause of its anti-inflammatory and analgesic prop-
erties (36).
KETOPROFEN IN CHRONIC RHEUMATIC
DISORDERS
Osteoarthritis 
Osteoarthritis (OA) is a common disorder of the
synovial joints. It is pathologically characterised by
focal areas of damage of the articular cartilage,
centred on load-bearing areas, associated with new
bone formation at the joint margins (osteophytosis),
changes in the subchondral bone, variable degrees
of mild synovitis, and thickening of the joint cap-
sule (37-39). OA is strongly age-related, being less
common before 40 years, but rising in frequency
with age, such that most people older than 70 years
have radiological evidence of osteoarthritis in some
joints. The clinical problems associated with these
pathological and radiographic changes include
joint pain related to use, short-lasting inactivity
stiffness of joints, pain on movement with a re-
stricted range, and cracking of joints (crepitus) (40-
42). However, the severity of joint disease is only
weakly related to that of the clinical problem. Re-
cent evidence indicates that peripheral pain sensi-
tisation is a feature of the osteoarthritic joint, per-
haps mediated by nerve growth factors or cytokines
(38). In addition to peripheral pain sensitisation,
central pain sensitisation at the spinal or cortical
level can occur in OA (43). Finally, the experience
of pain will be modulated by psychological, so-
cial, and other contextual factors. Pain in OA,
therefore, could be due to local and central sensi-
tisation of pain pathways resulting in normal stim-
uli becoming painful (43). For these reasons all pa-
tients should be educated and treated with exer-
cise, but if these measures fail, NSAIDs, physio-
therapy, and the use of aids and appliances should
be considered very early.
In an open-label randomised trial conducted in 113
patients with symptomatic hip osteoarthritis, a 4-
week treatment with either oral ketoprofen or in-
domethacin showed a significant efficacy of these
drugs in relieving osteoarticular pain, stiffness and
in improving quality of life. It is worth noting that
ketoprofen resulted in a much better safety profile
compared to indomethacin, with a lower number of
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Figure 1 - Ketoprofen plasmatic levels
after administration of ketoprofen cap-
sule 50 mg and ketoprofen lysine salt
(KLS) sachet or drops 80 mg (25, 26).
NSAIDs are more effective than simple analgesics
in relieving the signs and symptoms of active dis-
ease in established RA (50). These compounds
should be used as supplementary therapy and for
the shortest possible time. Among these drugs,
KLS is a NSAID with favourable anti-inflamma-
tory and analgesic properties and good penetration
into joint space. In an open study of one week du-
ration including twenty six patients with RA and
persistent knee effusion, it was demonstrated that
treatment with KLS and naproxen (NX) resulted in
a significant improvement in tenderness and fair,
but not significant, relief of the other clinical para-
meters (51). Moreover, synovial prostaglandin 2
(PGE-2) levels significantly decreased with both
drugs, with a mild prevalence of KLS compared to
NX (62.8% vs 51.7%). The overall efficacy and
tolerability were similar for both treatments, with
KLS being slight superior. The authors concluded
that the administration of KLS should be recom-
mended for the symptomatic treatment of RA since
this study confirms a favourable analgesic and an-
tiphlogistic activity and a good inhibitory effect of
KLS on PG levels into the joint space, even when
compared to naproxen. 
In another study involving 34 patients with
rheumatic diseases (20 of which were suffering
from RA), it was observed that oral treatment with
KLS resulted in a significant improvement in pain,
with a significant decrease in spontaneous pain
(p<0.001), tenderness, limitation of function and
duration of morning stiffness over a 10-day treat-
ment period in all the patients studied (45). More-
over, in 10 patients with a persistent knee effusion,
KLS was also observed to penetrate into the syn-
ovial fluid, causing a marked decrease in PGE-2
levels in the rheumatoid knee effusion with a per-
centage of inhibition of about 73%. These results
are particularly important in elderly patients. This
population is frequently affected by rheumatic dis-
eases such as OA and RA that are associated with
comorbidities, and generally require chronic
NSAIDs treatment. This raises the question of long
term safety and in this regard, ketoprofen has been
extensively studied in this particular population. In
particular, a prospective study designed to assess
the safety profile of ketoprofen over a 12-month
treatment period, including 823 patients over 65
years with OA and RA treated with oral ketopro-
fen, showed that at the end of the study, 521 pa-
tients (63.3%) remained on the drug regimen. The
study demonstrated that oral ketoprofen is safe for
the long-term treatment of elderly arthritic patients,
patients with adverse reactions or that withdrew
from the treatment (44). 
Efficacy of oral treatment with KLS has been
demonstrated with a significant improvement of
pain (p<0.01) in patients suffering from OA, with
a favourable clinical outcome 67.6% of patients
(45). 
Moreover, analgesic efficacy of acute oral admin-
istration of KLS has been shown to be greater than
that of acetylsalicylic acid (ASA), with an in-
creased circulating plasma levels of beta-endor-
phin and decreased levels of substance P. These
data suggest that the rapidly acting and continuous
analgesic activity in OA patients could be related
to the effect on beta-endorphin and substance P
levels in circulation (46).
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disease that primarily affects the peripheral
joints and often leads to tissue degradation and the
destruction of bone and cartilage (47). It usually
presents with pain, stiffness and symmetrical
swelling of the small joints of the hands and feet,
but may also involve other synovial joints. The in-
cidence of RA is estimated at 4-13 per 100,000 for
adult males and 13-36 per 100,000 for adult fe-
males. RA has a significant impact on a patient’s
physical, emotional and social functioning that of-
ten occurs very early in the disease. Current ther-
apies target the inflammatory consequences of au-
toimmune activation with the use of disease mod-
ifying antirheumatic drugs (DMARD) such as
methotrexate (MTX) and biologic DMARD (47).
The early use of effective DMARDs is a key point
in patients at risk of developing persistent and ero-
sive arthritis. Intensive treatment such as combi-
nation DMARDs plus steroids or biological thera-
pies can induce a high rate of remission, control of
radiological progression and provide better out-
come than DMARD monotherapy in early RA and
should be considered in patients at risk (48, 49).
Systemic glucocorticoids are effective in the short-
term relief of pain and swelling and should be con-
sidered, but mainly as a temporary therapy as part
of the DMARD strategy. Analgesics are used to
manage pain in all stages of the disease, often in
combination with other therapies to control the in-
flammatory process. NSAIDs have an immediate
effect on pain and stiffness, without influencing
the disease process. Substantial evidence, includ-
ing a Cochrane review, indicates that both the clas-
sical and cyclo-oxygenase 2 (COX-2) selective
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rapid and appreciable pain relief in patients with
gouty arthritis (62, 63). In a 7-day multicenter dou-
ble blind trial of oral ketoprofen versus in-
domethacin; including fifty-nine patients with
acute gouty arthritis, more than 90% of the patients
reported pain relief within the 1st day of treatment.
At the end of the study, most patients in both
groups were rated as having a marked improve-
ment both by both investigators and self-assess-
ment. Moreover, this study concluded that keto-
profen can be expected to provide relief from pain
of acute gouty arthritis within 24 hours with simi-
lar efficacy but less neurological side effects than
the standard drug indomethacin (64).
KETOPROFEN IN ACUTE RHEUMATIC
AND TRAUMATIC DISORDERS:
Acute rheumatic and traumatic diseases and soft
tissue injuries are often characterized by pain,
swelling and inflammation. They include sprains,
strains to muscles and ligaments, tendonitis and
bursitis, such as the common lateral epicondylitis
(tennis elbow) and trochanteric bursitis, regional
myofascial pain syndromes, with trigger points
similar to those of fibromyalgia but in a localized
distribution, low back pain and neurovascular en-
trapment, such as carpal tunnel syndrome and tho-
racic outlet syndrome. 
Soft tissue injuries
The first treatment for most acute soft tissue in-
juries (bruises, strains, sprains, tears) is to prevent,
stop and reduce swelling (65, 66). For more seri-
showing a high maintenance rate and a safety pro-
file similar to that seen in younger patients (52). 
Safety of ketoprofen in the elderly was evaluated
in a very large scale open study including approx-
imately 20,000 elderly patients (>60 years) suffer-
ing from painful rheumatic disorders. Oral keto-
profen given for a 4-week period showed an over-
all efficacy that was rated excellent/good in 74% of
cases by physicians and a very good risk/benefit ra-
tio in elderly patients compared with the general
population (53).
Gout
Gout is an inflammatory arthritic condition affect-
ing 1-2% of adults in the industrialised world that
occurs when uric acid crystals accumulate in joints
or other tissues (54-56). It is a common and in-
creasingly significant cause of acute and chronic
disability and impaired quality of life (57). Gout is
frequently characterized by recurrent attacks of
acute arthritis and sometimes it can lead to chron-
ic arthropathy, tophy depositions, and renal dis-
ease. Gout is also associated with a broad range of
comorbidities including cardiovascular disease,
chronic kidney disease, metabolic syndrome (56).
Standard management of acute attacks of gout in-
volves treatment with glucorticoids, NSAIDs and
colchicine, which remain the most widely recom-
mended drugs to treat acute attacks (56, 58). These
treatments should be started immediately to be
most effective and in order to reduce the risk for
acute gout flare (59-61). Several studies have eval-
uated the effects of ketoprofen in acute gout, show-
ing that intramuscular or oral administration of ke-
toprofen for 1 week was effective in inducing a
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Figure 2 - Analgesic effect on spon-
taneous pain measured with Scott-
Huskisson (0-8 hrs) scale after single
administration of ketoprofen lysine
salt 80 mg and placebo (68).
pain-related injuries, including tendinitis or
tenosynovitis, epicondylitis, traumatic bursitis,
sprains or articular contusion, compared the anal-
gesic efficacy of 1-week treatment of ketoprofen
(50mg/tid per os) versus ibuprofen (600mg/bid per
os). The results demonstrated that oral ketoprofen
had a significantly faster onset of pain relief, by 1.1
hours, than ibuprofen after the first dose and also,
produced a strongly higher maximum relief score.
Moreover, within 6 hours, 76% of patients treated
with ketoprofen obtained 50% pain relief (re-
sponders) as compared with 58% of the ibuprofen-
treated patients (p<0.05) reaching a greater pain
relief in a shorter time compared to ibuprofen (Fig.
3) (70).
Low back pain
Low back pain is one of the most common condi-
tions encountered in clinical practice and medica-
tions are the most commonly used type of treat-
ment. Acute low back pain is usually defined as the
duration of an episode of low back pain persisting
for less than 6 weeks; sub-acute low back pain as
low back pain persisting between 6 and 12 weeks;
and chronic low back pain as low back pain per-
sisting for 12 weeks or more. For most patients
with low back pain, regardless of the duration of
symptoms, paracetamol (acetaminophen) and
NSAIDs are the first-line choice for pain relief, as
recommended by the APS/ACP and European
guidelines (71-73). 
A systematic review of randomized trials found
that NSAIDs were effective for short-term symp-
tom relief, with an average improvement of about
8 points (on a 0-100 scale) compared with place-
bo in patients with acute back pain and about 12
points for chronic low back pain (74).Oral and in-
ous overuse injuries, physical therapy, and com-
plete rest associated with NSAIDs may be neces-
sary (67). A randomised, double blind clinical tri-
al of oral KLS (80mg/tid) versus placebo includ-
ing 120 patients with soft tissue disease as ten-
dinitis, bursitis and periarthritis, showed a signifi-
cant improvement in pain, tenderness and func-
tional limitation with a rapid and appreciable pain
relief. Analgesic activity of KLS was already sig-
nificant just 30 minutes after treatment (Fig. 2).
Moreover, no patient dropped out due to drug re-
lated adverse events and was observed to have an
excellent safety profile that was identical to that of
the placebo group. In conclusion, the study showed
that oral KLS is efficacious and safe in patients
with soft tissues diseases (68).
Another comparative multi centre study was con-
ducted with the main aim being to evaluate the ef-
ficacy and the tolerability of ketoprofen and di-
clofenac sodium in acute rheumatic and traumatic
conditions. One hundred and eighty patients treat-
ed with either ketoprofen or diclofenac for 15 days
(initially by i.m. injection, then followed by oral ad-
ministration) showed an improvement in pain
symptoms; in particular, the overall complete pain
relief of symptoms was observed in 25% of pa-
tients with ketoprofen versus 10% of patients with
diclofenac. Ketoprofen was found to be more ef-
fective in providing analgesia in most of the con-
ditions studied in the trial compared to diclofenac,
with higher number of patients experiencing com-
plete pain relief. The study also demonstrated a
better tolerability profile of ketoprofen versus di-
clofenac, rated as excellent-good in a higher per-
centage of patients (69).
An interesting multicenter, double-blind study
conducted in 165 patients with sports traumatic
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% Responders*Indicates a statistically significant 
P≤0.05 difference from ibuprofen (70).
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Figure 3 - Patient response to the first
dose based on pain relief scores in
terms of patients responders (58%
with ibuprofen 600 mg b.i.d. vs 76%
with ketoprofen 50 mg t.i.d). Respon-
ders were defined as patients who had
a pain relief score ≥50%.
Opioid drugs are probably recognised as the best
drug available in pain management, since they are
extremely effective due to their central analgesic
action. However, these drugs do cause side effects
that are important to be aware of (e.g., respiratory
depression, urinary retention, tolerance /depen-
dence, nausea, vomiting and pruritus) which may
limit their use and that have led many researchers
to seek a viable alternative. NSAIDs, supported by
the safe paracetamol and enriched by the intro-
duction of selective COX-2 inhibitors, are in part
substituting opioid drugs or, if nothing else, are
limiting their use when administered in combina-
tion. Among these, ketoprofen has been widely
studied in the treatment of postoperative or-
thopaedic pain in both the acute and the chronic
phase. Results are presented with regard to the var-
ious possible ways of administration, whether in-
travenous, intramuscular or oral.
Intravenous administration
The analgesic efficacy of intravenous ketoprofen
was investigated in a study by Castagnera et al.
(1988) in 60 patients undergoing orthopaedic
surgery detailed as follows: 16 of the spine (disc
surgery, spinal stabilization), 15 of the hip (pros-
thesis and femoral nailing), 15 of the knee (pros-
thesis, osteotomies, ligament plastics), 14 of the
foot and ankle (osteosynthesis or hallux valgus
surgery). Patients were treated with ketoprofen (2.5
mg /kg) injected at the onset of pain (T0) (77). Pain
was measured by Visual Analogic Scale (VAS) and
the Five-Item Verbal Rating Scale (VRS). Results
showed a reduction in pain intensity greater than
50% after 15 minutes and 85% 2 and 3 hours after
injection (p<0.001). Maximum analgesia obtained
at 120 minutes in knee and hip surgery and 180
tramuscular administration of ketoprofen have been
studied in different clinical trials in patients suf-
fering from lumbago. In a comparative 1-week
treatment study the efficacy and tolerability of in-
tra-muscular administration of ketoprofen and in-
domethacin were evaluated in 115 patients with
acute low back pain. In this study ketoprofen was
shown to significantly reduce global pain with a
more sustained improvement compared to in-
domethacin. Moreover, it is worth noting that a
higher percentage of ketoprofen-treated patients
experienced pain relief in just 1 hour compared to
the indomethacin group (61% vs 46.9%) (75). An-
other trial involving 155 patients with chronic lum-
bar pain showed that oral ketoprofen (150 mg/die)
demonstrated higher improvement rates 1 week af-
ter administration when compared to diclofenac
(75 mg/die), and thus, a faster onset of analgesic ef-
ficacy (71.4% of patients improved vs 62.36%, re-
spectively) (Fig. 4) (76).
KETOPROFEN IN THE POSTOPERATIVE
SETTING
Therapy with NSAIDs is widely used also in or-
thopaedic clinical practice. They are prescribed in
the treatment of osteomuscular pain in both the
acute and the chronic phase and provide excellent
support in postoperative analgesic therapy. 
However, the postoperative period in orthopaedic
surgery is not only characterized by the presence
of pain, but also by a series of therapeutic inter-
actions, complications, reparative phenomena of
the bone and soft tissue and orthopaedic and physi-
atric prescriptions, with which these drugs may
interact. 
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Figure 4 - Overall improvement rate
of all symptoms measured as per-
centage of patients improved, one
week after oral administration of ei-
ther ketoprofen 150 mg/die or di-
clofenac 75 mg/die (76).
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minutes in the spine and foot/ankle surgery. The
duration of analgesic effect was similar between
groups (8.5±1.5 hours). In conclusion, an analgesic
effect was observed in 96.6% of cases, meaning
that its analgesic activity combined with its anti-in-
flammatory effect make the intravenous adminis-
tration of ketoprofen safe and effective in post-op-
erative pain, reinforcing the consciousness that its
antalgic effect is not only due to a peripheral ac-
tion but also to a central effect.
Intramuscular administration
In 1992 Manani and colleagues studied 3 groups of
patients, each consisting of 25 units, in order to
compare the efficacy of intramuscular ketoprofen
and naproxen versus placebo in the management of
acute postoperative orthopaedic pain in the first 4
hours after the onset of moderate or severe pain
(78). If, 2 doses of NSAIDs were not effective, the
patient was treated with morphine (10 mg im). This
study showed that ketoprofen more markedly re-
duces postoperative pain, resulting in a lower de-
mand for additional doses of the same drug and
subsequent doses of morphine. 
Ketoprofen appeared to be more effective in pain
control compared with naproxen for its higher anal-
gesic properties. Naproxen, equipped with more
anti-inflammatory properties, may be more
favourably used in the treatment of deferred post-
operative surgery pain (78).
Efficacy of im administration of ketoprofen was
compared with diclofenac sodium, in a study by
Shah et al. (2003) (79). One hundred postoperative
patients treated with i.m. doses of ketoprofen (100
mg/bid) or diclofenac (75 mg/bid) for three days
showed an onset of analgesia with each drug with-
in 15-30 minutes; however, ketoprofen was supe-
rior to diclofenac in its onset of action, showing an
early response (i.e., 15-20 minutes in 92% of cas-
es as compared to 84% of cases with diclofenac)
(Fig. 5). This study demonstrated that ketoprofen
induced a longer duration of analgesic effect (12
hours) in a higher percentage of cases compared to
diclofenac with a lower rate of patients who need-
ed additional doses of opioid, demonstrating that it
is a more potent analgesic drug compared to di-
clofenac. 
Oral administration
More recently, Karvonen and co-workers (2008)
conducted an important randomized, double-blind,
placebo-controlled study to compare oral parac-
etamol and ketoprofen in reducing the side effects
of opioid analgesics after major orthopaedic
surgery (80). Sixty patients were investigated and
divided into 3 groups (oral placebo, paracetamol
and ketoprofen ) treated immediately after hip pros-
thesis. After surgery, all patients were provided
with a patient-controlled elastomer for administra-
tion of 0.05 mg over 5 minutes of intravenous bo-
lus fentanyl. The dose could be repeated at most
every 5 minutes with a maximum of 0.3 mg every
hour. Pain was measured by VAS, respiratory rate,
peripheral arterial saturation, heart rate, blood pres-
sure and side effects were recorded every 4 hours
for a total period of 20 hours. Results showed that
values of pain were similar in the 2 active groups:
patients in the ketoprofen group consumed on av-
erage 22% less fentanyl (p<0.05) compared with
the placebo group and 28% less than the paraceta-
mol group (p<0.05). Therefore, oral ketoprofen
may decrease the consumption of fentanyl while
paracetamol does no affect the consumption of opi-
oids postoperatively. There were no differences be-
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% Patients with complete pain relief
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Figure 5 - Onset of analgesia mea-
sured as percentage of patients with
complete pain relief after 15-20 min-
utes from the first injection of keto-
profen 100 i.m. or diclofenac 75 i.m.
(79).
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tween the 2 groups regarding side effects and pa-
tient satisfaction. 
Elastomeric devices 
NSAIDs are often used in the immediate postop-
erative period, in combination with other analgesic
drugs in elastomeric infusion devices. These treat-
ments allow a careful management of postoperative
pain with extending compliance of the patient. 
It is mandatory, however, that such combinations
in this context should be safe and stable over time
in order to avoid collateral effects or ineffective
therapy.
In 2005, Anacardio and colleagues conducted a
study to investigate the physicochemical compati-
bility of ketoprofen lysine salt with other analgesics
normally used in combination in elastomers (e.g.,
tramadol, ketorolac and morphine) (81). Two mol-
ecules can be considered pharmacologically com-
patible when, combined, show no significant
changes in their physicochemical properties for the
period necessary for their administration. Howev-
er, many substances, if combined, can lead to
changes in their therapeutic properties or to serious
side effects. Incompatibility can lead to visible
changes: precipitation, turbidity, colour or viscos-
ity changes, effervescence and formation of 2 lay-
ers of liquid which cannot be mixed. Chemical
degradation phenomena occur, such as hydrolysis,
oxidation, reduction, photo-degradation, racem-
ization and epimerization. Compositions also de-
pend on temperature and pH and are influenced by
the concentration of active ingredients, by the ex-
posure to light and by the ionic charge of the solu-
tion. Other alterations are not macroscopic and can
be analyzed by chromatography. The properties
that were investigated are colour, clarity, pH, con-
tent of active ingredient, as measured by HPLC
method with ultra violet rays before and after 7
days the association that took place at room tem-
perature and under light protection. Physical and
chemical parameters were measured immediately,
after 12 hours, 1, 2, 7 days. After 7 days there have
been no changes in colour, clarity or pH for all as-
sociations evaluated (ketoprofen lysine salt and tra-
madol, ketoprofen lysine salt and ketorolac, keto-
profen lysine salt and morphine) with a pH very
close to the physiological one, even the combina-
tion of ketoprofen lysine salt with morphine, that,
alone has a pH of 4.5. HPLC analysis demonstrat-
ed that there was not a decrease of more than 10%
of the nominal content of active ingredient in all
three associations. Therefore ketoprofen lysine salt
in vials can be used safely in combination in elas-
tomeric infusion devices with tramadol or ketoro-
lac for the period necessary for pain management
after orthopaedic surgery.
Ketoprofen versus opioid drugs 
In 1987 Langlais and colleagues performed a study
on 59 patients undergoing arthrolysis or knee lig-
amentoplasty, carpal or foot surgery, whose aim
was to compare the efficacy of ketoprofen and
pethidine in the treatment of postoperative pain
(82). Pain relief obtained was similar in both
groups (67% ketoprofen compared to 63% pethi-
dine) and also the duration of the effect was almost
the same (9.2 hours in the ketoprofen group and 8
hours in the pethidine group). No side effects were
reported in patients treated with ketoprofen. These
findings suggest that ketoprofen could be consid-
ered a good alternative to pethidine, especially af-
ter operations on joints that need early mobilization
and rehabilitation. 
These results were later confirmed by Hommeril
and co-workers (1994) thanks to a double-blind
study, randomized, which compared the effect of
intravenous ketoprofen (200 mg), followed by a
continuous elastomeric infusion of 12.5 mg/h for
13 hours, with the extradural administration of
morphine (4 mg) in 32 patients undergoing knee
and hip prostheses (83). Pain was measured by
VAS before surgery, 1 hour later and every 2 hours
thereafter. There was an average decrease of pain
by 44% 1 hour after administration in the group
treated with extradural morphine and 54% in the
ketoprofen group. There were no significant dif-
ferences between the 2 groups regarding the values
of pain reduction and the need for further analge-
sia. In 3 patients treated with extradural morphine
showing hypercapnia, naloxone (5 mg/kg/h) was
administered as an antidote. In the morphine group,
there was an increase in urinary retention. There-
fore, analyzing the risk-benefit rate, ketoprofen ap-
pears safer than morphine and equally effective in
the treatment of pain after intervention of hip or
knee prostheses.
Post-surgical calcifications and bone reparative
processes 
There are many immediate, late or chronic com-
plications which may develop after orthopaedic
surgery. Among these we wish to draw our atten-
tion to hip periprosthetic calcification and os-
teopenia (e.g., Sudeck’s atrophy), which can affect
any bone segment after prolonged immobilization
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(cast or orthesis) or if deprived of any mechanical
stimulus. Hip and pelvis surgery is often compli-
cated (60%) by the formation of heterotopic calci-
fication in soft tissues surrounding the operated
joint. They may become symptomatic, thus creat-
ing serious inconvenience to the patient and inter-
fere with rehabilitation, thereby increasing the re-
covery period. Sometimes their treatment requires
repeated cycles of physical and medical therapy
with high cost and resources. For years the pro-
phylactic effect of a prolonged postoperative anti-
inflammatory therapy against such calcification has
been proven. 
In a study by Vastel and co-workers (2005), the ef-
fect of ketoprofen and celecoxib was compared in
the prevention of hip periprosthetic calcification
(84). Classification was performed according to the
Brooker classification (stage 0-4) and evaluated
with an X-ray, for 2 groups of patients treated with
both drugs for a period of 7 days after surgery. In
both groups, a statistically significant reduction
(p=0.014, Fischer test) of calcification compared to
the control group was observed. There were no sta-
tistically significant differences between the 2 drug
groups. Patient groups were homogeneous, there
was no discernible differences in age, sex and un-
derlying disease. Based on the findings from this
study, it can be concluded that both drugs can be
safely used for prophylaxis of heterotopic hip cal-
cification. 
Regarding postoperative osteopenia, in 1996
Fiorentino and co-workers evaluated the efficacy of
ketoprofen as prophylaxis using a lower dose than
that used as an anti-inflammatory (85). It is known
that immobilization leads to a loss of bone mass in
both animals and humans. There is an increase in
bone resorption and a decrease in its formation. 
Experiments were performed on rats and osteope-
nia was induced by tail immobilization and mea-
sured at the level of the caudal vertebra and the
L2-L4 section by dual-energy X-ray absorptiome-
try. The caudal vertebra loses bone mineral densi-
ty (BMD) after tail immobilization. The L2-L4 lev-
el does not lose BMD because it is not affected by
immobilization. Treatment with ketoprofen was ex-
tended for 10 days. The results obtained showed
that immobilization only caused bone loss on the
caudal vertebra and an increase in the L2-L4 sec-
tion. Immobilization associated with ketoprofen
therapy resulted in decreased bone loss on the cau-
dal vertebra and no change in L2-L4 level. Treat-
ment with ketoprofen without immobilization re-
vealed no differences in BMD. These findings sug-
gest that the NSAIDs (ketoprofen in particular) re-
duce bone resorption and do not significantly alter
bone formation. 
Orthopaedic patients’ postoperative course is char-
acterized by reparative processes that mostly in-
volve the bone. The healing process of fractures
and bone defects is characterized by bone tissue re-
generation; this phenomenon is due to the stimu-
lation of specific growth factors that act on stromal
cells arising from the inflammatory process, and in
physiological conditions, may result in the forma-
tion of bone matrix. 
There is also evidence to suggest that ketoprofen
does not seem to interfere with these processes in
animal models (86, 87). One study compared the
effects of ketoprofen with a placebo control group
in tibial defects in rats digitally analyzing the bone
density up to 21 days after osteotomy (86). In the
control group, the optical density increased signif-
icantly in relation to time. The same correlation
was not observed in the ketoprofen group, as there
was a significant increase in optical density during
the first week and then a decrease from the twen-
ty-first day onwards. 
This study concluded that ketoprofen can be used
safely for the first 21 days after surgery. Similar re-
sults were reported by Matsumoto et al. (2008)
who wanted to compare 48 rats divided into three
groups; COX-2 inhibitors versus ketoprofen versus
placebo. In this study, histopathologic analysis, im-
munohistochemical (measuring the expression of
COX-2) and histomorphometric of the entire com-
plex (pre-resection zone, zone of resection and
post-resection zone) were performed (87). COX-2
was not completely inhibited by celecoxib during
the initial phase, but it was active in the central re-
gion in all 3 groups. 
After 7 days COX-2 was active in the granulation
tissue in the control and ketoprofen groups, but not
in the celecoxib group. In this group COX-2 was
no longer found in the bone marrow after 14 and
21 days, while it was still present in the other 2
groups. Even with these values there were no ef-
fects on bone repair. It may be concluded that in the
initial phases of inflammation the presence of the
enzyme was sufficient for prostaglandins activity
be efficient in releasing cells involved in the bone
repair process, then, and for this reason, COX-2 in-
hibitors may be used preferably in the acute phase
and for a short period of time. However, for more
prolonged therapy, ketoprofen seems safer, due to
the fact that it does not inhibit COX-2, even after
21 days. 
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Even in the case of bone grafts ketoprofen has been
shown to be a safe drug, as demonstrated by a re-
cent study by van Der Heide (88). In this study,
which was performed on 27 goats, ketoprofen and
meloxicam were not observed to interfere with the
integration of a bone graft, either autograft, washed
allograft, or allograft, after 7 days of administra-
tion. Finally, in another recent pre-clinical study, 30
rabbits were subjected to bilateral posterolateral
spinal fusion on a single level using autologous
graft harvested from iliac crest (89). This study
showed that ketoprofen did not increase the risk of
non-union compared with tramadol with a similar
rate of fusion (53%) and non-union (47%) in both
groups. 
Cardiovascular diseases
Cardiovascular (CV) disease is now one of the
leading extra-articular causes of morbidity and
mortality in RA patients with rheumatic diseases,
who show an increased susceptibility to develop-
ing cardiac complications. Many studies have
shown that coronary artery disease is one of the
most common causes of death in RA and seems to
occur at a younger age than in the general popula-
tion (90-92). However, all cardiac structures can be
affected during the course of RA (valves, the con-
duction system, the myocardium, endocardium and
pericardium, and the coronary arteries), and cardiac
complications include a variety of clinical mani-
festations such as pericarditis, myocarditis, my-
ocardial fibrosis, arrhythmias, alterations in con-
duction, coronary diseases and ischemic cardiopa-
thy, valvular disease, pulmonary hypertension and
heart failure. Patients with gout not only suffer po-
tentially disabling and deforming arthritic disease,
but are also at a high risk for CV and metabolic dis-
orders that includes a multitude of interrelated ath-
erosclerotic risk factors, including abdominal obe-
sity, insulin resistance, atherogenic dyslipidemia,
elevated blood pressure, and elevated plasma glu-
cose (93, 94). As these are all associated with an
unfavourable prognosis, for this reason some pa-
tients need an anticoagulant or cardiovascular ther-
apy. In addition, patients undergoing orthopaedic
surgery, who are often elderly with associated un-
derlying diseases, are treated with different drugs
belonging to different classes, in particular, with
oral anticoagulants, which may be affected by the
association with NSAIDs. 
All NSAIDs, including ketoprofen, should be used
with caution in patients treated with anticoagulant
and/or antihypertensive drugs. There are several
mechanisms by which NSAIDs may increase the
likelihood and severity of bleeding in patients treat-
ed with warfarin (95, 96). Two major types of phar-
macokinetic interactions have been reported: 1)
displacement of warfarin from plasma albumin and
2) inhibition of the metabolism of warfarin by
NSAIDs. In vitro and animal studies on ketopro-
fen have demonstrated that displacement of war-
farin is unlikely to be of clinical significance (97).
A placebo-controlled, double-blind study on
healthy volunteers, already stabilized on warfarin,
treated with ketoprofen (100 mg twice daily for 7
days) demonstrated that ketoprofen did not affect
the protrombin time. In particular, there was no
change in coagulation cascade parameters and no
clinical evidence of bleeding (24, 95). 
A study on 40 patients with hypertensive disease
demonstrated a lack of superiority of nimesulide -
a preferential COX-2 inhibitor - over ketoprofen,
considering the effect on circadian, nocturnal an di-
urnal mean values of arterial blood pressure. The
study clearly indicates that nimesulide is not safer
than ketoprofen in the treatment of patients with ar-
terial hypertension since both drugs induced a
small increase of arterial blood (98). 
Other trials have been conducted with the aim to
evaluate the effect of ketoprofen in patients treat-
ed with antihypertensive drugs (e.g., captopril or
acebutol etc.). The results of these studies showed
that ketoprofen does not interfere with blood pres-
sure control or heart rate in hypertensive patients
being treated with beta-blockers and diuretics (99),
nor affect glomerular filtration rate or blood pres-
sure in essential hypertensive patients treated with
a converting enzyme inhibitor such as captopril,
suggesting that ketoprofen is a safe choice when
short-term treatment with a NSAID is indicated in
patients (100).
Another problem in patients receiving NSAIDs
could be the increased risk of acute myocardial in-
farction (AMI). Selective COX-2 inhibitors and non
selective COX inhibitors exhibit this undesired ef-
fect. Of the non selective COX inhibitors, diclofenac
has been shown to have far highest relative risk of
developing AMI, whereas ketoprofen is suggested
to be safer (101-104). The association between AMI
in humans and use of NSAIDs has been demon-
strated in several studies, but the mechanisms are
still unclear. In an animal model, the interaction of
diclofenac and ketoprofen with cardioactive drugs
was assessed on the basis of ECG records after the
infusion of adrenalin, verapimil or lidocaine to rats
treated with diclofenac and ketoprofen versus con-
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trol (105). This study showed no occurrence of car-
diotoxic action of diclofenac and ketoprofen in ECG
patterns, but diclofenac caused significantly lower
sodium plasma concentrations with increased potas-
sium concentrations. These findings may in part ex-
plain the increased risk of AMI in patients treated
with diclofenac over ketoprofen.
CONCLUSIONS
In clinical practice, the majority of patients with
chronic rheumatic diseases are elderly, suffer from
different other diseases such as cardiovascular dis-
eases or metabolic disorders and could be treated
with multiple drugs that may interact with
NSAIDs. Ketoprofen has been demonstrated to be
generally well tolerated in elderly patients, and no
interactions with anticoagulant drugs have been
observed.
Ketoprofen has been used extensively in the man-
agement of all tissue diseases and postoperative
pain, it is effective and safe also in patients with
acute rheumatic pain, including related bursitis,
tendinitis, periarthritis and low back pain, allowing
a fast onset of analgesic activity. Efficacy and safe-
ty of ketoprofen has been demonstrated by several
evidences that underline how ketoprofen is highly
effective and compares favourably to other
NSAIDs, such as diclofenac or ibuprofen. Keto-
profen is able to provide better analgesic control,
greater and faster pain relief with an overall very
good tolerability profile. Thus, we can conclude
that ketoprofen may represent an optimal choice in
the treatment of pain in these patient populations.
Ketoprofen has also been proved a valuable mole-
cule useful in various stages in the postoperative
course of patients undergoing orthopaedic surgery.
Regarding the management of postoperative pain,
we can conclude that it may reduce the use or the
dose of the opioid drugs, if not fully replace them,
thus avoiding the side effects of these therapies. In
the postoperative setting, ketoprofen can provide a
longer duration of analgesia and a significantly
higher overall efficacy when compared to di-
clofenac. Ketoprofen can be used safely in elas-
tomeric combination without losing its effective-
ness and its anti-inflammatory analgesic effect
should not be forgotten, often useful in patients
with osteo-muscular disorders. Its effectiveness in
preventing heterotopic calcification and osteopenia
after immobilization has been demonstrated, de-
creasing in this way the rate of such complications
that often delay the functional recovery of the pa-
tient. It has been proven to be a safe drug con-
cerning its interaction with bone reparative process-
es, both in terms of the phenomena of bone regen-
eration and for the eventual integration of bone
grafts that are often used in traumatology. 
Based on these clinical evidences, we can conclude
that ketoprofen may be a valid treatment option for
postoperative pain relief.
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SUMMARY 
Ketoprofen is a drug belonging to the family of non-steroidal anti-inflammatory drugs (NSAIDs). The present review
examines the main available clinical evidence of ketoprofen in the treatment of acute and chronic pain, of both rheumat-
ic and traumatic origin, as well as postoperative pain. Ketoprofen has shown to be an excellent choice of drug for the
treatment of chronic pain in patients with osteoarthritis, rheumatoid arthritis or gout, demonstrating a high level of ef-
ficacy with good tolerability also in elderly patients. Even in the treatment of acute forms of pain such as bursitis, ten-
dinitis and back pain, ketoprofen compares favourably to other NSAIDs (e.g., ibuprofen and diclofenac) in terms of
efficacy. Ketoprofen has been shown to be effective also for the treatment of post-operative pain, particularly in the
orthopaedic field, with an efficacy similar to opioids in some studies. In this setting, some evidence indicates that ke-
toprofen exhibits additional important benefits, showing to be effective in the prophylaxis of heterotopic calcification
following hip or pelvic major intervention, without affecting the bone healing process. Moreover, the use of ketopro-
fen in elastomeric pump in combination with opioids or other NSAIDs has proven to be effective and safe. In conclu-
sion, available data confirm that ketoprofen is effective and well tolerated, through different administration routes, for
the treatment of various forms of rheumatic, traumatic and post-surgical pain, and may therefore be considered as a
valid therapeutic option for these patients.
Parole chiave - Ketoprofen, NSAID, post-operative pain, rheumatic pain, orthopaedics.
Key words - Ketoprofene, FANS, dolore post-operatorio, dolore reumatico, ortopedico.
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